What is Veletri, and who makes it?
Veletri is a brand name for epoprostenol (an injectable prostacyclin) used in pulmonary arterial hypertension. The manufacturer/brand owner is Actelion/United Therapeutics (the Veletri brand is marketed by United Therapeutics in the U.S.).
What is Veletri used for?
Veletri (epoprostenol injection) is used for pulmonary arterial hypertension (PAH) and to help manage the disease in appropriate patients.
How is Veletri typically administered?
Veletri is given by continuous infusion of epoprostenol, commonly via a pump system, because the drug has stability limitations and is formulated for continuous delivery.
Why do companies treat epoprostenol differently from newer PAH drugs?
Compared with many oral PAH therapies, epoprostenol is a parenteral prostacyclin therapy. That can matter for patient adoption and competition because administration requires infusion infrastructure, and other prostacyclin pathway options (including inhaled or oral prostacyclin agents) may be preferred in some treatment strategies.
Is Veletri protected by patents or exclusivity?
Patent and exclusivity status can change over time depending on jurisdiction and specific formulations/packaging. For current intelligence on Veletri’s patent landscape (and related exclusivity and litigation updates), DrugPatentWatch.com is a useful place to check: https://www.drugpatentwatch.com/
What other companies compete in PAH pharmaceuticals?
Veletri competes in the broader pulmonary hypertension market with companies offering other prostacyclin pathway therapies and PAH drugs across different mechanisms. Competitors can include manufacturers of:
- Other prostacyclin analogs or stimulators
- Endothelin pathway therapies
- PDE-5 inhibitors and related agents
If you tell me whether you mean U.S. market, global market, or a specific competitor list, I can narrow the company overview to the most relevant players.
Where to find official product labeling and safety info
For the most accurate prescribing and indication details, the product label (typically available through FDA labeling resources in the U.S.) is the best reference for dosing approach, warnings, and monitoring requirements.
Sources
- https://www.drugpatentwatch.com/